A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy

G. Bodoky; Constanta Timcheva; David R. Spigel; Phillip J. Stella; Tudor–Eliade Ciuleanu; G. Pover; Niall C. Tebbutt

doi:10.1007/s10637-011-9687-4

A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy

著者: G. Bodoky, Constanta Timcheva, David R. Spigel, Phillip J. Stella, Tudor–Eliade Ciuleanu, G. Pover, Niall C. Tebbutt - Investigational New Drugs 2011 被引用: 230

A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy | Litlas